> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Safety Alert on Immune Globulin Products
- URL: https://www.fdaweb.com/fda-safety-alert-on-immune-globulin-products/
- Published: 2025-03-12T12:00:00.000Z
- Updated: 2026-09-14T14:55:04.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5158814

An FDA [safety alert ](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/voluntary-lot-withdrawals-immune-globulin-intravenous-igiv-and-immune-globulin-subcutaneous-igsc-0?ref=fdaweb.com)says several manufacturers have recalled several lots of immune globulin intravenous and immune globulin subcutaneous due to a higher rate of allergic/hypersensitivity-type reactions, some of which were considered medically significant. “Hypersensitivity and anaphylactic/anaphylactoid reactions are a known risk with immune globulin products,” the alert says. Affected products include Grifols’ Xembify, ADMA Biologics’ Bivigam, Octapharma’s Panzyga, and Grifols’ Gamunex-C.